Medication Adherence in Patients With Glaucoma After Cancer Diagnosis

Hou, Chiun Ho; Lin, Ken Kuo; Js, Lee; Pu, Christy

doi:10.1016/j.ajo.2020.01.004

Cited by 5 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous study indicated that the new onset of cancer can impede glaucoma medication adherence, which is likely caused by demanding treatments associated with cancer. 26 For people with disability, however, only certain types of disability reduce adherence; thus, the reasons may go beyond the burden of increased treatment demands. For example, we found that patients in a vegetative state were not likely to receive glaucoma medication.…”

Section: Discussionmentioning

confidence: 99%

“…Strategies to improve medication adherence for glaucoma treatments should target the diverse needs of people with various disabilities. Our previous study indicated that the new onset of cancer can impede glaucoma medication adherence, which is likely caused by demanding treatments associated with cancer . For people with disability, however, only certain types of disability reduce adherence; thus, the reasons may go beyond the burden of increased treatment demands.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Medication Adherence in Patients With Glaucoma and Disability

Hou

2021

JAMA Ophthalmol

Self Cite

View full text Add to dashboard Cite

IMPORTANCE People with disabilities tend to have lower medication adherence. Glaucoma medication adherence has been scantly studied for people with disability. OBJECTIVE To determine whether disability leads to reduced glaucoma medication adherence and whether this decrease varies by type of disability. DESIGN, SETTING, AND PARTICIPANTSThis population-based case-control study enrolled individuals with glaucoma and without disability, who were followed up until they received disability certification. All patients in Taiwan with confirmed glaucoma in 1 or both eyes were identified using National Health Insurance claims data. All patients with glaucoma who required glaucoma medication adherence (confirmed glaucoma, suspected glaucoma, and patients with ocular hypertension) and had newly obtained disability status after December 31, 2013, were identified and matched to counterparts without disability based on age and sex.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Medication Adherence in Patients With Glaucoma and Disability

Hou

2021

JAMA Ophthalmol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Because the MPR is dependent on the period, we calculated 3 sets of MPRs for analysis [ 8 ]: (1) MPRs 1 year before and 1 year after disability onset (1-year MPRs), (2) MPRs 2 years before and 2 years after disability onset (2-year MPRs, excluding the 1-year MPRs), and (3) MPRs averaged over the first and second years before and after disability onset (2-year average MPRs over a 730-day period).…”

Section: Methodsmentioning

confidence: 99%

Medication adherence in patients with type 2 diabetes after disability onset: a difference-in-differences analysis using nationwide data

Chen,

Lee,

2024

BMC Med

Self Cite

View full text Add to dashboard Cite

Background Effectively managing the coexistence of both diabetes and disability necessitates substantial effort. Whether disability onset affects adherence to type 2 diabetes medication remains unclear. This study investigated whether disability onset reduces such adherence and whether any reduction varies by disability type. Methods This study used the National Disability Registry and National Health Insurance Research Database from Taiwan to identify patients with type 2 diabetes who subsequently developed a disability from 2013 to 2020; these patients were matched with patients with type 2 diabetes without disability onset during the study period. Type 2 diabetes medication adherence was measured using the medication possession ratio (MPR). A difference-in-differences analysis was performed to determine the effect of disability onset on the MPR. Results The difference-in-differences analysis revealed that disability onset caused a reduction of 5.76% in the 1-year MPR (P < 0.001) and 13.21% in the 2-year MPR (P < 0.001). Among all disability types, organ disabilities, multiple disabilities, rare diseases, and a persistent vegetative state exhibited the largest reductions in 2-year MPR. Conclusions Policies aimed at improving medication adherence in individuals with disabilities should consider not only the specific disability type but also the distinct challenges and barriers these patients encounter in maintaining medication adherence.

show abstract

“…A major problem in glaucoma treatment, as in other chronic diseases, is patients' non-adherence. Although blindness caused by glaucoma can be avoided if glaucoma is diagnosed and correctly treated in the early stages, numerous studies have shown the problem of intermittent therapy [55][56][57][58][59][60]. A study conducted by Tsai et al [55] identified 71 reasons for non-adherence, which were divided into four groups: situational/environmental factors, medication regimen, patents' factors, and provider's factors.…”

Section: Novel Drug Delivery Systemsmentioning

confidence: 99%

Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions

et al. 2020

View full text Add to dashboard Cite

Glaucoma is considered to be one of the biggest health problems in the world. It is the main cause of preventable blindness due to its asymptomatic nature in the early stages on the one hand and patients’ non-adherence on the other. There are several approaches in glaucoma treatment, whereby this has to be individually designed for each patient. The first-line treatment is medication therapy. However, taking into account numerous disadvantages of conventional ophthalmic dosage forms, intensive work has been carried out on the development of novel drug delivery systems for glaucoma. This review aims to provide an overview of formulation solutions and strategies in the development of in situ gel systems, nanosystems, ocular inserts, contact lenses, collagen corneal shields, ocular implants, microneedles, and iontophoretic devices. The results of studies confirming the effectiveness of the aforementioned drug delivery systems were also briefly presented.

show abstract

Medication Adherence in Patients With Glaucoma After Cancer Diagnosis

Cited by 5 publications

References 37 publications

Medication Adherence in Patients With Glaucoma and Disability

Medication Adherence in Patients With Glaucoma and Disability

Medication adherence in patients with type 2 diabetes after disability onset: a difference-in-differences analysis using nationwide data

Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions

Contact Info

Product

Resources

About